Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 9:30 AM ET.

Avalo Therapeutics Stock Up 1.4%

NASDAQ:AVTX opened at $16.02 on Tuesday. The stock’s 50-day simple moving average is $15.89 and its 200 day simple moving average is $15.61. The firm has a market capitalization of $296.53 million, a PE ratio of -2.99 and a beta of 0.84. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $20.72.

Analyst Upgrades and Downgrades

AVTX has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Avalo Therapeutics in a report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Guggenheim began coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective for the company. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Caligan Partners LP acquired a new position in shares of Avalo Therapeutics in the third quarter valued at approximately $10,592,000. Balyasny Asset Management L.P. bought a new position in Avalo Therapeutics in the 3rd quarter valued at approximately $10,390,000. Vanguard Group Inc. boosted its position in Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after buying an additional 525,696 shares during the period. Millennium Management LLC grew its holdings in Avalo Therapeutics by 380.2% during the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after acquiring an additional 522,548 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in Avalo Therapeutics by 806.2% during the 4th quarter. Marshall Wace LLP now owns 507,550 shares of the company’s stock worth $9,217,000 after acquiring an additional 451,541 shares during the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.